A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis
Public ClinicalTrials.gov record NCT03144687. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis
Study identification
- NCT ID
- NCT03144687
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Incyte Corporation
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- Itacitinib Drug
- Ruxolitinib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 25, 2018
- Primary completion
- Mar 13, 2020
- Completion
- May 31, 2021
- Last update posted
- Jun 15, 2022
2018 – 2021
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Oncology Associates | Tempe | Arizona | 85284 | — |
| UC Irvine Medical Center | Orange | California | 92868 | — |
| Anschutz Cancer Pavilion - University Of Colorado | Aurora | Colorado | 80045 | — |
| Rocky Mountain Cancer Center | Colorado Springs | Colorado | 80907 | — |
| Rocky Mountain Cancer Center | Denver | Colorado | 80218 | — |
| Norwalk Hospital | Norwalk | Connecticut | 06856 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| University of Michigan Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Providence Cancer Center | Southfield | Michigan | 48075 | — |
| Nebraska Cancer Specialist | Omaha | Nebraska | 68124 | — |
| University Of New Mexico Cancer Center | Albuquerque | New Mexico | 87102 | — |
| Duke University Medical Center | Durham | North Carolina | 27710 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Willamette Valley Cancer Institute | Eugene | Oregon | 97401 | — |
| Consultants in Medical Oncology and Hematology, PC | Broomall | Pennsylvania | 19008 | — |
| Texas Oncology - Round Rock Cancer Center | Round Rock | Texas | 78681 | — |
| Texas Oncology San Antonio | San Antonio | Texas | 78240 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03144687, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 15, 2022 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03144687 live on ClinicalTrials.gov.